| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Ista Pharmaceuticals, Inc. |
| 15279 Alton Parkway, Building 100, Irvine, CA 92618 * (949) 788-6000 |
| Business Description | The company discovers and develops novel therapeutics for diseases and conditions of the eye. |
| Offering Information Company has | |||
| Trading As | ISTA (NASNTL) | Industry | Manufacturing (SIC 3845) |
| Type of Stock Offered | Common Shares | Filing Date | 4/5/00 |
| Domestic Shares Offered | 3,000,000 | Offer Date | 8/21/00 |
| Foreign Shares Offered | 0 | Filing Range | $13.00 - $15.00 |
| Company Shares | 3,000,000 | Offer Price | $10.50 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.735 |
| Gross Proceeds | $31,500,000 | Selling | $0.370 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 15,930,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| CIBC World Markets | Lead Manager | (212) 667-7400 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Thomas Weisel Partners LLC | Co-manager | (415) 364-2500 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 0.000 | 0.000 | 0.000 | - | - |
| Income from Oper. | - | - | -6.918 | -9.670 | -14.302 | - | - |
| Net Income | - | - | -6.752 | -9.624 | -14.284 | - | - |
| E.P.S | - | - | -4.890 | -6.640 | -8.800 | - | - |
| Revenue Growth (%) | - | - | - | - | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -10.25 | - | - | ||||
| Cash Flow - Inv. | -0.10 | - | - | ||||
| Cash Flow - Fin. | 8.66 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 3.02 | Current Assets | 1.64 | Current Ratio | 0.25 |
| Total Liab. | 11.68 | Current Liab. | 6.64 | Debt Ratio | 386.67% |
| Total Equity | -8.66 | Working Cap. | -4.99 | Debt to Equity Ratio | - |
| Cash | 0.71 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to fund clinical trials and preclinical research, with a particular focus on Vitrase, to finance the possible acquisition of complementary technologies, products or businesses and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Skadden, Arps, Slate, Meagher & Flom |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Biotechnology Investments Ltd. | ||
| Allergan Pharmaceuticals (Ireland) Ltd., Inc. | ||
| Note: represents ownership of 5% or more prior to the offering. | ||